FDA accepts Cogent's drug application with priority review for GIST treatment

May 28, 2026 8:01 AM

Cogent Biosciences Inc. (NASDAQ: COGT) announced the U.S. Food and Drug Administration has accepted its New Drug Application for bezuclastinib ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found